Xuelan Tao – Trademark Portfolio
Entity Type: 01
Xuelan Tao owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as CLDEAR, AMBERBOY, CHANGESKY, and PETAFOREST. Of these, 4 are registered and 6 are pending. The portfolio spans 7 Nice Classification classes, led by Class 9 (Computers & Electronics) and Class 3 (Cosmetics & Cleaning). Headquartered in Hubei Province.
Dafa Temple Town, Wuxue City,
No. 75, Limaohongyuan, Limaohong Village
Hubei Province 435400 , CN
Showing of trademarks Trademarks
Trademark Classifications
Xuelan Tao's trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Frequently Asked Questions
How many trademarks does Xuelan Tao have?
Xuelan Tao has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 pending.
What trademark classes does Xuelan Tao file in?
Xuelan Tao files trademarks across 7 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 3 (Cosmetics & Cleaning), Class 20 (Furniture), Class 21 (Housewares), Class 10 (Medical Apparatus). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Xuelan Tao's most well-known trademarks?
Xuelan Tao's registered trademark portfolio includes well-known marks such as CLDEAR, AMBERBOY, CHANGESKY, and PETAFOREST. These are among 4 currently registered trademarks in the portfolio.
What is Xuelan Tao's trademark registration success rate?
Xuelan Tao has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 6 applications are pending review.